I agree with @kmakm
On the research I read the endocrine therapy was only beneficial for local recurrence or locally advanced ...nodes and preventing contralactal breast cancer. It didn't make any difference in reduction of distant mestastes it seems.
The updated guidelines are based on the results of six large trials looking at whether taking an aromatase inhibitor for more than 5 years offered additional benefits. The studies found that extended aromatase inhibitor treatment didn’t seem to improve overall survival, but it did significantly reduce the risk of breast cancer recurrence and the risk of breast cancer developing in the opposite breast.
Here's the full article. It's all doing my head in really.
https://www.breastcancer.org/research-news/asco-recommends-extended-hormonal-tx-for-some
